aTyr Pharma, Inc. (LIFE)

2,0000 +0,0700 (+3,63%) Alla chiusura: 04:00PM EDT

aTyr Pharma, Inc.

10240 Sorrento Valley Road
Suite 300
San Diego, CA 92121
United States
858 731 8389
https://www.atyrpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 56

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Sanjay S. Shukla M.D., M.S.	President, CEO & Director	768,18k	N/D	1972
Ms. Jill M. Broadfoot	Chief Financial Officer	544,75k	N/D	1962
Ms. Nancy E. Denyes Krueger	General Counsel & Corporate Secretary	518,2k	N/D	1968
Xiang-Lei Yang Ph.D.	Founder	N/D	N/D	N/D
Ms. Ashlee Dunston	Director of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Peter Villiger	Vice President of Corporate Development	N/D	N/D	N/D
Ms. Danielle Campbell	VP of Human Resource	N/D	N/D	N/D
Dr. Leslie Nangle Ph.D.	Vice President of Research	N/D	N/D	N/D
Dr. Ying J. Buechler Ph.D.	Executive Director of Biologics Development & Manufacturing	N/D	N/D	N/D
Dr. David J. King Ph.D.	Scientific Consultant	327,31k	N/D	1959

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di aTyr Pharma, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.